
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is well-positioned to continue its strong financial performance, driven by the success of its flagship drug Brukinsa and its other approved drugs Beqalzi and Tevimbra. The company also has an extensive pipeline of clinical trials, giving it potential for future growth and market share in the oncology therapeutics market. Management's focus on diversity and ethical conduct also bodes well for the company's long-term success.
Bears say
BeOne Medicines is a global oncology company that has a strong focus on developing affordable and accessible oncology medicines. Its flagship product, Brukinsa, has shown promising results in its Phase 3 clinical trial and is on track to generate over $4 billion in global revenues in 2026. The company also has a robust pipeline of over 30 assets in various phases and disease areas, demonstrating their commitment to innovation. However, there is a potential for regulatory and commercial setbacks, emergence of new competitors, and risks to management execution, which could impact the company's overall success.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares